SAB Biotherapeutics Inc.
SABS | NASDAQ
$3.49
+$0.10 (+2.95%)
Sep 22, 2026, 12:32 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 17 | -1.03 | -0.90 | -1.37 | -12.40 | 13.62 |
PEG Ratio | -0.16 | 0.02 | -0.01 | 0.04 | 0.07 | 0 |
PS Ratio | n/a | 26.54 | 16.96 | 1.07 | 3.51 | 4.96 |
PB Ratio | 0.48 | 1.35 | 0.66 | 0.83 | 5.54 | 7.03 |
P/FCF Ratio | -1.58 | -1.01 | -1.50 | -1 | -23.84 | -100.54 |
P/OCF Ratio | -1.61 | -1.02 | -1.51 | -1.09 | 107.47 | 27.40 |
OCF/S Ratio | n/a | -2.59K | -1.12K | -98.14 | 3.26 | 18.11 |
Debt / Equity Ratio | 0.04 | 0.18 | 0.10 | 0.19 | 0.22 | 0.21 |
Quick Ratio | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 | 3.11 |
Current Ratio | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 | 3.11 |
Asset Turnover | n/a | 0.03 | 0.03 | 0.47 | 0.75 | 0.98 |
Interest Coverage | -203.41 | -134.77 | -120.76 | -95.89 | -45.48 | 43.82 |
Return on Equity | 8.76% | -131.33% | -73.64% | -60.34% | -44.47% | 51.57% |
Return on Assets | 7.68% | -77.17% | -50.27% | -36.82% | -21.13% | 35.58% |
Return on Invested Capital | -30.02% | -115.89% | -50.78% | -77.51% | -23.18% | 43.61% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | -262.41% | -67.26% | 86.23% | 97.28% | 100% |
Net Profit Margin | n/a | -2.58K% | -1.88K% | -78.40% | -28.16% | 36.42% |
Pretax Profit Margin | n/a | -2.58K% | -1.88K% | -78.29% | -28.16% | 36.42% |
Operating Profit Margin | n/a | -3.24K% | -1.7K% | -120.98% | -22% | 37.22% |
FCF Margin | n/a | -2.62K% | -1.13K% | -107.20% | -14.71% | -4.94% |
EBITDA Margin | n/a | -2.19K% | -1.7K% | -63.26% | -24.96% | 38.26% |
Add to Watchlist
Select watchlists to add or remove SABS